Shingrix - Infectious Diseases

Relevant Publications

Post-marketing surveillance of 10,392 herpes zoster vaccines doses in Australia.

Issue Release: 2024

Anti-Herpes Zoster Vaccination of Fragile Patients in Hospital Setting: A Nudge Intervention in Italy.

Issue Release: 2024

Incidence of Herpes Zoster and Postherpetic Neuralgia and Herpes Zoster Vaccination Uptake in a US Administrative Claims Database.

Issue Release: 2024

Rational optimization of glycoprotein E (gE)-encoding mRNA for improved Varicella-zoster Virus mRNA vaccine development.

Issue Release: 2024

Lipo-pam™ adjuvanted herpes zoster vaccine induces potent gE-specific cellular and humoral immune responses.

Issue Release: 2024

Time to talk to adults with rheumatic diseases about herpes zoster vaccination.

Issue Release: 2024

Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques.

Issue Release: 2024

Community-Based Cross-Sectional Assessment Survey On Herpes Zoster Vaccination Practices.

Issue Release: 2024

Hypermetabolic Axillary Lymphadenopathy After Shingrix Vaccination for Varicella Zoster Virus.

Issue Release: 2024

Engineering Escherichia coli for constitutive production of monophosphoryl lipid A vaccine adjuvant.

Issue Release: 2024

IFN-α armed gE elicits superior immunogenicity compared to unmodified antigens and flagellin armed gE in mice.

Issue Release: 2024

Risedronate-functionalized manganese-hydroxyapatite amorphous particles: A potent adjuvant for subunit vaccines and cancer immunotherapy.

Issue Release: 2024

A nanoparticle vaccine displaying varicella-zoster virus gE antigen induces a superior cellular immune response than a licensed vaccine in mice and non-human primates.

Issue Release: 2024

Comparison of the Immunogenicity of the LZ901 Vaccine and HZ/su Vaccine in a Mouse Model.

Issue Release: 2024

Scattered pustular lesions 10 days after Shingrix vaccination in systemic sclerosis patient after successful autologous non-myeloablative haemopoietic stem-cell transplantation.

Issue Release: 2024

Cost-Effectiveness of the Recombinant Zoster Vaccine Among People Living With HIV in Japan.

Issue Release: 2024

Glycoprotein E-Displaying Nanoparticles Induce Robust Neutralizing Antibodies and T-Cell Response against Varicella Zoster Virus.

Issue Release: 2024

Potent and long-lasting humoral and cellular immunity against varicella zoster virus induced by mRNA-LNP vaccine.

Issue Release: 2024

Co-administration of the adjuvanted recombinant zoster vaccine with other adult vaccines: An overview.

Issue Release: 2024

What would have happened anyway? Population data source considerations when estimating background incident rates of adverse events following immunisation to inform vaccine safety.

Issue Release: 2024

What are the Symptoms of Herpes?

What are the Complications of Untreated Gonorrhea?

What Has the Global Fund Achieved?

What are the Implications of Colonization in Healthcare Settings?

How do ACTs Work?

What are the controversies surrounding Dengvaxia?

What are Natural Killer (NK) Cells?

What Tests are Performed on Stool Samples?

How Can Hygiene Practices be Implemented in Healthcare Settings?

What is the Impact of Vaccinations on Public Health?

Partnered Content Networks

Relevant Topics